Phenobarbital

Phenobarbital

SCHEMBL11114624

CCC1(c2ccccc2)C(=O)N=C(O)NC1=O

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
TSHR P16473 2/20 0.51
MEN1 O00255 1/20 0.51
CYP1A2 P05177 1/20 0.51
POLB P06746 1/20 0.51
APEX1 P27695 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
LMNA P02545 2/20 0.51
MMP2 P08253 5/20 0.49
MMP9 P14780 5/20 0.49
MMP3 P08254 2/20 0.49
CYP2C19 P33261 2/20 0.47
MMP13 P45452 1/20 0.38
GSK3A P49840 4/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
GSK3B P49841 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4384790 0.81 GABRA1 (0.40) KMT2ATSHRMEN1CYP1A2POLB
Phenobarbital SCHEMBL42037 0.80 KMT2A (0.50) KMT2ATSHRMEN1CYP1A2POLB
Phenobarbital SCHEMBL7775273 0.76 MMP9 (0.53) KMT2ATSHRMEN1CYP1A2POLB
SCHEMBL4379252 0.75 LMNA (0.46) KMT2ATSHRMEN1CYP1A2POLB
Phenobarbital SCHEMBL28099657 0.74 MMP2 (0.80) KMT2ATSHRMEN1CYP1A2POLB
Phenobarbital SCHEMBL2592325 0.74 MMP2 (0.80) KMT2ATSHRMEN1CYP1A2POLB
Phenobarbital SCHEMBL18825042 0.74 MMP2 (0.80) KMT2ATSHRMEN1CYP1A2POLB
Phenobarbital SCHEMBL16583 0.74 MMP2 (0.80) KMT2ATSHRMEN1CYP1A2POLB
Phenobarbital SCHEMBL25330743 0.73 KMT2A (0.49) KMT2ATSHRMEN1CYP1A2POLB
Phenobarbital SCHEMBL11529160 0.73 MMP9 (0.73) KMT2ATSHRMEN1CYP1A2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12161695-B2 GABA A receptor agonists for treatment of disorders influenced by dysfunction BETA cells DIAMYD MEDICAL AB (SE) 2024-12-10 US claimed
US-20210113586-A1 NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES DIAMYD MEDICAL AB (SE) 2021-04-22 US claimed
EP-3755314-A1 GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS Diamyd Medical AB (SE) 2020-12-30 EP claimed
EP-3756007-A1 NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES Diamyd Medical AB (SE) 2020-12-30 EP claimed
US-20200384086-A1 GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS DIAMYD MEDICAL AB (SE) 2020-12-10 US claimed
US-20200138830-A1 ENHANCING GABA'S ABILITY TO MODULATE IMMUNE RESPONSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-05-07 US claimed
EP-3642206-A1 ENHANCING GABA'S ABILITY TO MODULATE IMMUNE RESPONSES The Regents of The University of California (US) 2020-04-29 EP claimed
WO-2019164446-A1 NEW USE AND METHODS OF MODULATING IMMUNE RESPONSES DIAMYD MEDICAL AB (SE) 2019-08-29 WO claimed
WO-2019162403-A1 GABA A RECEPTOR AGONISTS FOR TREATMENT OF DISORDERS INFLUENCED BY DYSFUNCTION BETA CELLS DIAMYD MEDICAL AB (SE) 2019-08-29 WO claimed
WO-2018236955-A1 ENHANCING GABA'S ABILITY TO MODULATE IMMUNE RESPONSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-12-27 WO claimed
US-20180235916-A1 ENHANCING BETA CELL REPLICATION AND/OR SURVIVAL NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2018-08-23 US claimed
EP-3362069-A1 ENHANCING BETA CELL REPLICATION AND/OR SURVIVAL The Regents of The University of California (US) 2018-08-22 EP claimed
US-20170296532-A1 COMPOSITIONS FOR CONTROL OF DRUG ABUSE KYDES PHARMACEUTICALS (US) 2017-10-19 US claimed
WO-2017066240-A1 ENHANCING BETA CELL REPLICATION AND/OR SURVIVAL THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-04-20 WO claimed
US-20130295170-A1 COMPOSITIONS FOR CONTROL OF DRUG ABUSE KYDES PHARMACEUTICALS LLC (US) 2013-11-07 US claimed
US-12161695-B2 GABA A receptor agonists for treatment of disorders influenced by dysfunction BETA cells DIAMYD MEDICAL AB (SE) 2024-12-10 US disclosed
US-11992495-B2 Enhancing GABA's ability to modulate immune responses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-05-28 US disclosed
WO-2017066240-A1 ENHANCING BETA CELL REPLICATION AND/OR SURVIVAL THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-04-20 WO disclosed
US-20130295170-A1 COMPOSITIONS FOR CONTROL OF DRUG ABUSE KYDES PHARMACEUTICALS LLC (US) 2013-11-07 US disclosed
US-4428887-A Method of producing mono-substituted terminal diesters MONSANTO COMPANY (US) 1984-01-31 US disclosed